Inventor

WEISSMAN IRVING L

US130 patents

⚠️ This page may combine multiple inventors who share the name “WEISSMAN IRVING L”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

WEISSMAN IRVING L

UNIV LELAND STANFORD JUNIOR

Humanized and chimeric monoclonal antibodies to CD47

Humanized and chimeric monoclonal antibodies to CD47

Ex vivo methods for targeting or depleting acute myeloid leukemia cancer stem cells

Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies

Methods for achieving therapeutically effective doses of anti-CD47 agents for treating cancer

Methods for manipulating phagocytosis mediated by CD47

Methods for manipulating phagocytosis mediated by CD47

High affinity PD-1 agents and methods of use

High affinity PD-1 agents and methods of use

Markers of acute myeloid leukemia stem cells

Mammalian myeloid progenitor cell subsets

Methods of identifying and isolating stem cells and cancer stem cells

Mammalian common lymphoid progenitor cell

Mammalian myeloid progenitor cell subsets

Use of β-catenin in the expansion of stem and progenitor cells

Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody

High affinity Sirp-alpha reagents and methods of using

Markers of acute myeloid leukemia stem cells

Markers of acute myeloid leukemia stem cells

Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling

Methods for achieving therapeutically effective doses of anti-CD47 agents

Methods for manipulating phagocytosis mediated by CD47

Methods of manipulating phagocytosis mediated by CD47

Methods of manipulating phagocytosis mediated by CD47

Methods of manipulating phagocytosis mediated by CD47

CD47 targeted therapies for the treatment of infectious disease

Use of WNT inhibitors to augment therapeutic index of chemotherapy

Feeder layer and serum independent embryonic stem cells

Methods for diagnosing and evaluating treatment of blood disorders

Dosing parameters for CD47 targeting therapies to hematologic malignancies

Isolation of mesenchymal stem cells

Markers of acute myeloid leukemia stem cells

Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies

Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody

Markers of acute myeloid leukemia stem cells

Markers of acute myeloid leukemia stem cells

Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPα antibody therapy

Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance

Methods for determining responsiveness to an anti-CD47 agent

Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody

High affinity SIRP-alpha reagents and methods of using

Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist

High affinity PD-1 agents and methods of use

CD47 targeted therapies for the treatment of infectious disease

WEISSMAN IRVING L

Synergistic anti-CD47 therapy for hematologic cancers

Homogeneous mammalian hematopoietic stem cell composition

Isolation and use of melanoma cancer stem cells

JAISWAL SIDDHARTHA

Methods of treating acute myeloid leukemia by blocking CD47

CALIFORNIA INST OF TECHN

Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof

UNIV TUFTS

Optical array device and methods of use thereof for screening, analysis and manipulation of particles